Other
Megestrol Acetate
0
Pipeline Programs↗
1
Active Trials↗
1
Companies Involved↗
Megestrol Acetate is an early-stage landscape with 0 programs across 1 company. The most active players are Par Pharmaceutical, Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
12
clinical trials
Completed8 · 67%
Withdrawn2 · 17%
Terminated1 · 8%
Recruiting1 · 8%
Clinical Trials
Trial Activity
12 trials
Bioequivalence of Nomegestrol Acetate (NOMAC) and Estradiol (E2) in Commercial Versus Phase 3 Pivotal Clinical Batches of NOMAC-E2 Tablets (P06328)
Completed·—·Phase 1·NCT01345786·158 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)